Kamat - Figure 5
How common is BCG failure?
FIG. 5: How common is BCG failure? In a study by Hemdan et al,[1] BCG was compared with chemotherapy using epirubicin plus interferon-α2b. As shown in this Figure, the initial response rates to BCG were good, with about 80% recurrence-free survival at 6 months. Over time, however, especially between 48 and 60 months, 40% of these tumors relapsed. Hence, in a real-world situation, about 40% of patients experienced recurrence of tumor after BCG therapy.
References
Hemdan T, Johansson R, Jahnson S, et al; Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol. 2014;191:1244−9 doi: http://dx.doi.org/10.1016/j.juro.2013.11.005
